

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
is exempted from a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/729,387
		Filing Date	December 3, 2003
		First Named Inventor	Francis T. GILES
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	STROMIX-007
Sheet	1	of	2

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark if the English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



OCT 27 2004

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/729,387
Sheet	2	of	2	Filing Date	December 3, 2003
				First Named Inventor	Francis T. GILES
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	STROMIX-0007

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CM		"FDA Approves Gleevec for Leukemia Treatment" FDA Consumer, US Dept. of Health, Educ. And Welfare, Public Health Services, US, vol. 4, July 2001, pg. 8, XP001145827	
CM		Giles F. et al. "Phase II Study of Troxatyl in Patients with Chronic Myeloid Leukemia in Blastic Phase (CML-BP)" Blood, W.B. Saunders Company, Orlando, FL, US, vol. 98, no. 11, part 2, (2001), pg. 2588, XP009007253	
CM		B. Scappini et al, "In vitro effects of ST1571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", 2002 American Cancer Society, May 15 94(10):2653-62	
		R. Nimmanapalli et al, "Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias", Curr Opin. Oncol. 2002 Nov; 14(6):616-620	
		A. Hochhaus et al, "Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy", Leukemia 2002 Nov, 16(11):2190-6	
		M. Beran et al, "Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase", Cancer Res. 1993 Aug 1;53(15):3603-10	
		B. Kasper et al, "Favorable therapeutic index of a p210 BCR-ABL specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukaemia progenitors", Cancer Chemother Pharmacol (1999) 44:433-438	
		C.L. Sawyers, "Chronic myeloid leukemia" The New England Journal of Medicine, 1999: 340:1330-1340	
		B. J. Druker et al, "Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia", Blood 1998; 94(Suppl. 1):368a	
CM		Giles F. J. et al., "Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia", Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. United States, February 1, 2001, Vol. 19, No. 3, pp. 762-771, XP009007304	
		"Gleevec (STI-571) for chronic myeloid leukemia", Medical Letter on Drugs and Therapeutics, New Rochelle, NY, US, June 11, 2001, Vol. 43, No. 1106, pp. 49-50, XP001038570	
		M. Kotekci et al, "Isolation and characterization of a near-haploid human cell line", Exp Cell Res. 1999 Nov 1;252(2):273-80	
		A. Klejman et al, "Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI-571", Oncogene 2002, Aug 29; 21(31):5868-76	
		BS Andersson et al, "KBM-7 a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts", Leukemia 1995 Dec; 9(12):2100-8	
		J. Toplak et al, "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells", Leukemia (2001) 15:342-347	

Examiner Signature	CM	Date Considered	3-20-05
--------------------	----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 21 2004

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

**Substitute for form 1449AVTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT.**

(use as many sheets as necessary)

She

1

1

**Complete If Known**

Application Number	10/729,387
Filing Date	December 3, 2003
First Named Inventor	Francis T. GILES
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	PHARMA-139

U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Signature  Considered 9-18-05

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the indicator, as indicated on the document under WIPO Standard ST.12, if possible. <sup>6</sup> Applicant is to place a check mark if the English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/729,387	
(use as many sheets as necessary)			Filing Date	December 8, 2003	
Sheet	2	of	2	First Named Inventor	Francis T. GILES
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	PHARMA-139

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
CM		Orsolic, Nada et al. "Troxatyl and ST1571 Combination Therapy for Chronic Myeloid Leukemia: Preclinical In Vitro and In Vivo Evaluation", Blood, vol. 100, no. 11, (2002), Abstract No. 3107, XP0009027132	
CM		"FDA Approves Gleevec for Leukemia Treatment" FDA Consumer, US Dept. of Health, Educ, And Welfare, Public Health Services, US, vol. 4, July 2001, pg. 6, XP001145627	
CM		Giles F. et al. "Phase II Study of Troxatyl in Patients with Chronic Myeloid Leukemia in Blastic Phase (CML-BP)" Blood, W.B. Saunders Company, Orlando, FL, US, vol. 98, no. 11, part 2, (2001), pg. 258B, XP009007253	

Examiner Signature	CM	Date Considered	320-05
--------------------	----	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.